Business Responsibility and Sustainability Reporting for Financial year ended March 31, 2025.

Fermenta Biotech has submitted its BRSR for FY 2024-25 to BSE as part of its Annual Report. The company manufactures Vitamin D3, niche APIs, biotech and nutraceutical products, contributing 85.5% of turnover, with Vitamin D3 products alone at 76%. Exports account for 52% of revenue across around 60 countries, with operations spread over 4 national plants and 1 office. The workforce stands at 532 permanent employees (only 6.77% female) and 97 permanent workers, with women making up 33.33% of the 9-member Board. Key positives: zero work-related fatalities or injuries, zero complaints on POSH/child labour/forced labour/discrimination, 100% employees trained on human rights, full minimum wage compliance, and employee turnover rate dropped sharply from 28.6% to 14.83%. Grievances were low — 2 shareholder and 7 customer complaints, all resolved. Reported standalone turnover for FY 2023-24 was ₹30,709.04 lakhs with net worth of ₹31,422.61 lakhs.